TO: The Honorable Brian E. Frosh, Chairman  
Members, Senate Judicial Proceedings Committee  
The Honorable Edward R. Reilly

FROM: Joseph A. Schwartz, III  
Pamela Metz Kasemeyer  
J. Steven Wise

DATE: February 16, 2012

RE: SUPPORT WITH AMENDMENT – Senate Bill 310 – Criminal Law – Controlled Dangerous Substances – Synthetic Cannabinoids

The Maryland State Medical Society (MedChi), which represents over 7,600 Maryland physicians and their patients, supports Senate Bill 310 with amendment.

Synthetic cannabinoids are rapidly becoming a significant public health challenge. They are chemically engineered substances that are similar to the active ingredients in marijuana and produce a similar effect when smoked or ingested. They have become a popular alternative to marijuana, particularly with youth and have been linked to tachycardia, seizures, hallucinations and other responses commonly found with drug abuse.

Senate Bill 310 adds to Schedule I, the Schedule for controlled dangerous substances, several chemical compounds known as synthetic cannabinoids. Designation of these chemicals as Schedule I drugs will effectively ban them in Maryland as Schedule I cannot be prescribed, manufactured, possessed, dispensed, imported, exported or sold. These substances have no safe use, present a high potential for drug abuse and should be banned from the marketplace.

However, MedChi would also note the need to include research language to the bill to ensure that if Maryland adds chemicals to its Schedule I list that are not also included on the federal Schedule I that legitimate research on those chemicals is not negatively impacted. There may be legitimate research being conducted on these chemicals. Failure to include the
appropriate research language could inadvertently prohibit or negatively impact these research efforts. To that end, MedChi urges the Committee to work with those institutions that can properly craft the language to insure the intended objectives of the legislation are achieved. With its amendment noted, MedChi urges a favorable report.

For more information call:
Joseph A. Schwartz, III
Pamela Metz Kasemeyer
J. Steven Wise
410-269-1618